Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), has named Richard Hancock as interim president and chief executive officer, effective immediately. Mr. Hancock will also continue to serve on Avid's board of directors. He succeeds Roger Lias, who has resigned from the company and its board of directors. In the meantime, the company is commencing a search for a permanent chief executive. Mr. Hancock has worked in the biotechnology industry for more than 30 years in various operational and executive roles and possesses significant experience in cGMP manufacturing, regulatory affairs, scale up, operational protocols and team management. Throughout his career, he is credited with building teams and companies dedicated to bringing innovative biologics including therapeutics and vaccines to patient populations through innovative process development, production and manufacturing services.